+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Immunotherapy"

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014-18 - Product Thumbnail Image

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014-18

  • Report
  • August 2019
  • 42 Pages
  • Global
Reimbursement and Payer Management of Immune Checkpoint Inhibitors - Product Thumbnail Image

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

  • Report
  • November 2018
  • 80 Pages
  • Global
From
Global Oncology Drugs Market 2018-2024 - Product Thumbnail Image

Global Oncology Drugs Market 2018-2024

  • Report
  • March 2018
  • 102 Pages
  • Global
From
Specific Cancer Immunotherapy Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Specific Cancer Immunotherapy Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • January 2024
  • 84 Pages
  • Global
From
Immuno Oncology Therapy Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Immuno Oncology Therapy Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2023
  • 99 Pages
  • Global
From
Oncology and Cancer Treatment Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Thumbnail Image

Oncology and Cancer Treatment Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • March 2025
  • 119 Pages
  • Global
From
Recombinant Human Interleukin-2 for Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Thumbnail Image

Recombinant Human Interleukin-2 for Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • March 2025
  • 81 Pages
  • Global
From
Non-Specific Cancer Immunotherapy Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Non-Specific Cancer Immunotherapy Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • January 2024
  • 80 Pages
  • Global
From
Cancer Immunotherapy Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Cancer Immunotherapy Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2023
  • 104 Pages
  • Global
From
Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 94 Pages
  • Global
From
Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 417 Pages
  • Global
From
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 100 Pages
  • Global
From
Anal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Anal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 216 Pages
  • Global
From
Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 342 Pages
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

  • Drug Pipelines
  • April 2019
  • 85 Pages
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 39 Pages
  • Global
From
Molecular Targets and Cancer Therapeutics (Part 2) - Product Thumbnail Image

Molecular Targets and Cancer Therapeutics (Part 2)

  • Book
  • April 2023
Frontiers in Anti-Cancer Drug Discovery: Volume 12 - Product Thumbnail Image

Frontiers in Anti-Cancer Drug Discovery: Volume 12

  • Book
  • August 2021
Personalized Immunotherapy for Tumor Diseases and Beyond - Product Thumbnail Image

Personalized Immunotherapy for Tumor Diseases and Beyond

  • Book
  • November 2020
From
Immuno-Oncology: Unicorns, China And The Perfect Storm - Product Thumbnail Image

Immuno-Oncology: Unicorns, China And The Perfect Storm

  • Newsletter
  • June 2025
  • 12 Pages
  • China
From
Loading Indicator

Cancer Immunotherapy is a type of Immune Disorders Drugs that uses the body's own immune system to fight cancer. It works by stimulating the body's natural defense system to recognize and attack cancer cells. This type of therapy is used to treat a variety of cancers, including melanoma, lymphoma, and leukemia. It can also be used to treat other types of cancer, such as breast, lung, and colorectal cancer. Cancer Immunotherapy is a rapidly growing field, with many new treatments being developed. It is an important part of the overall cancer treatment landscape, as it can provide a more targeted approach to treating cancer. It can also be used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Some of the companies in the Cancer Immunotherapy market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are developing a range of treatments, including monoclonal antibodies, vaccines, and cell-based therapies. Show Less Read more